

Table S2. Clinical and laboratory characteristics of patients with and without left atrial thrombus on transesophageal echocardiography (derivation cohort).

Variable	Patients with LAA thrombus (n=59)	Patients without LAA thrombus (n=974)	<i>p</i>
Age [years]	67 (60-74)	60 (53-66)	<0.0001
Female [n (%)]	21 (36%)	326 (33%)	0.78
BMI [kg/m ²]	29 (25-33) <i>n=37</i>	29 (26-32) <i>n=920</i>	0.84
EHRA class	3 (2-3) <i>n=15</i>	3 (2-3) <i>n=705</i>	0.86
Type of atrial fibrillation (AF) [n (%)]			
Paroxysmal AF	10 (17%)	622 (64%)	<0.0001
Persistent AF	36 (61%)	301 (31%)	<0.0001
Permanent AF	13 (22%)	51 (5.2%)	<0.0001
Type of procedure planned [n (%)]			
Cardioversion	8 (14%)	191 (20%)	0.31
Ablation	51 (86%)	783 (80%)	0.31
Concomitant diseases [n (%)]			
Hypertension	38 (64%)	622 (64%)	1.00
Dyslipidemia	18 (31%)	403 (41%)	0.10
Diabetes	18 (31%)	142 (15%)	0.003
Coronary artery disease	14 (24%)	137 (14%)	0.06
Previous myocardial infarction	9 (15%)	58 (6.0%)	0.01
Peripheral artery disease	1 (1.7%)	14 (1.4%)	0.59
Vascular disease (CAD and/or PAD)	14 (24%)	142 (15%)	0.06

Heart failure	24 (41%)	102 (10%)	<0.0001
Previous ischemic stroke/TIA	7 (12%)	49 (5.0%)	0.04
Previous peripheral embolism	2 (3.5%)	10 (1.0%)	0.14
Previous hemorrhagic stroke	0 (0%)	2 (0.2%)	1.00
Biological valve prosthesis	2 (3.4%)	7 (0.7%)	0.09
Mechanical valve prosthesis	1 (1.7%)	3 (0.3%)	0.21
Chronic respiratory disease	7 (12%)	46 (4.7%)	0.03
Liver disease	1 (1.8%)	14 (1.5%)	0.58
Hyperthyroidism	6 (10.2%)	93 (9.6%)	0.82
Hypothyroidism	4 (6.8%)	88 (9.0%)	0.81
Malignancy	4 (6.8%)	54 (5.5%)	0.57
Hyperuricemia	2 (3.4%)	55 (5.7%)	0.77
Smoking	19 (32%)	344 (35%)	0.13
Thromboembolic risk			
CHADS ₂ score	2 (1-2)	1 (0-2)	<0.0001
CHA ₂ DS ₂ -VASc score	3 (2-4)	2 (1-3)	<0.0001
CHA ₂ DS ₂ -VASc score			
[n (%)]			
= 0	1 (1.7%)	173 (18%)	<0.0001
= 1	13 (22%)	294 (30%)	<0.0001
≥ 2	45 (76%)	507 (52%)	<0.0001
Antithrombotic treatment [n (%)]			
VKA	30 (51%)	434 (46%)	0.21
NOAC	23 (39%)	430 (45%)	0.78
- dabigatran	13 (57%)	197 (46%)	0.29
- rivaroxaban	10 (43%)	232 (54%)	0.30
- apixaban	0 (0%)	1 (0.1%)	1.00

Antiplatelets	2 (3.4%)	67 (6.9%)	0.42
Laboratory parameters			
Hemoglobin [g/dL]	14 (13-15)	14 (13-15)	0.16
WBC [K/ μ L]	7.5 (6.3-9.1)	7.4 (6.3-8.7)	0.44
Platelet count [K/ μ L]	199 (155-243)	218 (186-250)	0.07
GFR [mL/min/1.73 m ²]	56 (47-79)	69 (57-81)	0.003
Transthoracic echocardiography*			
Ejection fraction [%]	54 (49-60) <i>n=11</i>	56 (45-60) <i>n=131</i>	0.65
Left atrial diameter [cm]	4.8 (4.4-5.2) <i>n=14</i>	4.5 (4.1-4.8) <i>n=401</i>	0.04
Transesophageal echocardiography*			
LAA emptying velocity [cm/s]	22 (19-27) <i>n=53</i>	60 (40-80) <i>n=961</i>	<0.0001
Dense SEC [n (%)]	17 (29%)	26 (2.7%)	<0.0001
SEC [n (%)]	30 (51%)	132 (14%)	<0.0001

* performed during index hospitalization

AF - atrial fibrillation, BMI - body mass index, EHRA - European Heart Rhythm Association, CAD - coronary artery disease, GFR - glomerular filtration rate, LAA - left atrial appendage, NOAC - non-vitamin K antagonist oral anticoagulants, PAD - peripheral artery disease, SEC - spontaneous echo contrast, TIA - transient ischemic attack, VKA - vitamin K antagonists, WBC - white blood cells